Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664986 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL10607843 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL9980754 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL30471514 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL9980671 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL7057277 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL7439787 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL30471384 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL148100 | 0.92 | CA1 (0.52) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL148099 | 0.92 | CA1 (0.52) | KMT2ACTSKCTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5461176-A | Reacting alanine methyl ester with oxalyl chloride, treating with ammonia in methanol, reducing amides with diborane in tetrahydrofuran, neutralizing with sodium ethoxide to yield free amine | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-10-24 | — | — | US | claimed |
| EP-0577753-A1 | BIS-NAPHTHALIMIDES CONTAINING AMINO-ACID DERIVED LINKERS AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-01-12 | — | — | EP | claimed |
| WO-1992017453-A1 | BIS-NAPHTHALIMIDES CONTAINING AMINO-ACID DERIVED LINKERS AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-15 | — | — | WO | claimed |
| EP-0506008-A1 | Bis-naphthalimides containing amino-acid derived linkers as anticancer agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-09-30 | — | — | EP | claimed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20260085118-A1 | CONJUGATE OF ANTI-CTLA-4 ANTIBODY ACTIVATED BY TUMOR MICROENVIRONMENT AND USE THEREOF | YAFEI SHANGHAI BIOLOGY MEDICINE SCIENCE & TECH CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| US-20260042773-A1 | NOVEL CAMPTOTHECIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| EP-4652183-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250352662-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4631952-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-12440576-B2 | Antibody drug conjugates comprising sting agonists | MERSANA THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-0403605-A1 | ELASTASE INHIBITING POLYMERS AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-12-27 | — | — | EP | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0396709-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-11-14 | — | — | EP | disclosed |
| EP-0368449-A2 | Elastase inhibiting polymers and methods to produce them | Digenis, George Alexander (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0367514-A2 | Human leukocyte elastase inhibitors and methods for producing and using same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-05-09 | — | — | EP | disclosed |
| WO-1990004409-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-05-03 | — | — | WO | disclosed |
| WO-1990002558-A1 | ELASTASE INHIBITING POLYMERS AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-03-22 | — | — | WO | disclosed |
| US-4277395-A | OF ELASTASE; OLIGOPEPTIDES | RICHARDSON-MERRELL INC. (US) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440576-B2 | Antibody drug conjugates comprising sting agonists | STING1, CGAS, IFNAR1 | KMT2A 2297/4885CTSK 1976/4885CTSS 2082/4885 |
| US-20260042773-A1 | NOVEL CAMPTOTHECIN ANALOGS AND IMMUNOCONJUGATES THEREOF | FCGR2A, FCGR3B, FCGR1A | KMT2A 2585/4885CTSK 3205/4885CTSS 3004/4885 |
| US-20250352662-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | KMT2A 2297/4885CTSK 1976/4885CTSS 2082/4885 |
| US-20260085118-A1 | CONJUGATE OF ANTI-CTLA-4 ANTIBODY ACTIVATED BY TUMOR MICROENVIRONMENT AND USE THEREOF | FCGR2A, FCGR3B, CD274 | KMT2A 2188/4885CTSK 477/4885CTSS 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.